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The circadian clock in mammalian organisms is generated by a
transcription–translation feedback loop that controls many bio-
chemical pathways at the cellular level and physiology and behav-
ior at the organismal level. Cryptochrome (Cry) is a key protein in
the negative arm of the transcription–translation feedback loop. It
has been found that Cry mutation in cells with p53-null genotype
increased their sensitivity to apoptosis by genotoxic agents. Here
we show that this increased sensitivity is due to up-regulation of the
p53 gene family member p73 in response to DNA damage. As a
consequence,when tumors arising fromoncogenic Ras-transformed
p53−/− and p53−/−Cry1−/−Cry2−/− cells are treated with the antican-
cer drug oxaliplatin, p53−/− tumors continue to grow whereas
p53−/−Cry1−/−Cry2−/− tumors exhibit extensive apoptosis and
stop growing. This finding provides a mechanistic foundation for
overcoming the resistance of p53-deficient tumor cells to apopto-
sis induced by DNA-damaging agents and suggests that disruption
of cryptochrome function may increase the sensitivity of tumors
with p53 mutation to chemotherapy.
The circadian clock is a global regulatory system that generatesrhythmic changes with ∼24-h periodicity in many cellular and
organismal functions. At the molecular level the clock is com-
posed of four gene groups, CLOCK/NPAS2, BMAL1, Cry1/2, and
Per1/2, that generate a transcription–translation feedback loop
(TTFL): The CLOCK/NPAS2-BMAL1 heterodimer transacti-
vates the transcription of cognate genes includingCry1/2 and Per1/
2; the Cry and Per proteins, in turn, inhibit CLOCK-BMAL1 after
a time lag to close the regulatory loop and generate rhythmic
expression or subcellular location of the clock proteins (1–5). The
circadian clock directly controls the expression of ∼10% of the
genes in a given tissue (6). In addition, the clock network is in-
tegrated within all of the major cellular signaling and metabolic
pathways (2–4). As a consequence, disruption of the clock is ex-
pected to affect cellular and organismal behavior inmultiple ways.
We found that circadian clock disruption by cryptochrome
(Cry) mutation (7) or Cry down-regulation in a p53-null (8, 9)
background renders cells more sensitive to genotoxic agents, such
as UV, by making them more prone to apoptosis (Figs. S1 and
S2) (7). To gain some insight into the mechanism by which Cry
mutation sensitizes cells to apoptosis, we considered the p53-
independent pathways for intrinsic apoptosis. Specifically, we
focused on contribution of the p73 gene to intrinsic apoptosis. The
p73 protein along with p63 and p53 constitute the p53 family (10–
12). Of these, p53 is the primary tumor suppressor, which prevents
cancer mainly by promoting apoptosis in response to DNA
damage or oncogenic transformation. In the absence of p53, the
other two members of the family, in particular p73, a structural
and functional homolog of p53 (10–12), can substitute for p53 as
the proapoptotic tumor suppressor (13–17). Hence, when we
discovered that p53−/−Cry1−/−Cry2−/− (hereafter p53KOCryDKO)
cells have increased sensitivity to apoptosis compared with p53−/−
(p53KO) cells (7), we reasoned that this might have been caused by
an elevated level of p73 in p53KOCryDKO, in particular after DNA-
damaging treatment, as it is known that p73 is a damage-inducible
gene (18). To test this idea, we compared p73 levels and apoptosis
in p53KO and p53KOCryDKO cells after UV irradiation or oxali-
platin treatment. We found that these genotoxic treatments in-
duce high levels of p73 in cryptochrome mutant cells and
significantly enhance apoptosis and clonogenic cell death in
p53KOCryDKO cells relative to p53KO cells. This finding suggests
that disruption of cryptochrome function may be used as an ad-
juvant in cancer chemotherapy with platinum-based drugs.
Results
Effect of Cryptochrome Mutation on p73 Expression. We found that
under our assay conditions neither p73 nor p63 is detectable be-
fore DNA damage but both are strongly induced after UV irra-
diation (Fig. 1A). Importantly, however, whereas the Cry
mutation in p53-null background had no effect on p63 induction
by UV, it enhanced the rates of both p73 mRNA and protein
synthesis by a factor of about 10 (Fig. 1A and Figs. S3 and S4). We
should note, however, that the enhanced induction of p73 by UV
in p53KOCryDKO cells is not unique to cells with p53-null genotype.
We find essentially the same dose–response and enhanced in-
duction of p73 inCry1−/−Cry2−/− (CryDKO) cells as in p53KOCryDKO
cells (Fig. S3), indicating that enhanced expression of p73 in Cry-
null cells is independent of the p53 status of the cell.
To ascertain that the enhanced apoptosis in p53KOCryDKO was
in fact dependent upon p73, we compared the UV-induced apo-
ptosis in p53KOCryDKO and p53KO cells before and after siRNA
knockdown of p73. The results indicate that both the residual
apoptosis observed in p53KO and the enhanced apoptosis seen in
p53KOCryDKO cells are drastically reduced when p73 is down-
regulated (Fig. 1B and Fig. S5), suggesting that the enhanced
induction of p73 in p53KOCryDKO is responsible for the increased
apoptosis seen in these cells.
Regulation of p73 by the Circadian Clock. These findings suggest a
unique regulatory mechanism that is both circadian clock- and
DNA damage-dependent. To test this model, we analyzed p73
levels and apoptotic response to DNA damage in p53KO cells after
down-regulation of the negative (Cry1/2 or Per1/2) and positive
(BMAL1) elements of the core circadian TTFL. The results are
shown in Fig. 1C and Figs. S6 and S7. Down-regulation of either
Cry1/2 or Per1/2 enhances UV-induced p73 synthesis and apo-
ptosis. Interestingly, down-regulation of either Cry1 or Cry2 yields
results similar to down-regulation of both genes with regard to
UV-induced p73 levels and the extent of apoptosis as probed by
caspase activity (Fig. 1C) and clonogenic survival (Fig. S6). Im-
portantly, both of these effects are reversed by down-regulation of
BMAL1 (Fig. 1C and Fig. S6), supporting the conclusion that
the expression of p73 is controlled both by DNA damage and by
the circadian clock, a unique and unprecedented regulatory
mechanism.
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Control of p73 Expression by DNA Damage and the Circadian Clock.
Next, we wished to understand how clock disruption by Cry mu-
tation leads to elevated p73 levels. As this increase was dependent
on both the circadian TTFL and DNA damage, we investigated
the p73 promoter for clock-related sequence elements. We found
that the p73 promoter region up to 4 kbp preceding the tran-
scription initiation site did not reveal a canonical E box or the
variant E′-box elements, which are key sequence elements in the
promoters of most first-order clock-controlled genes. Then, we
considered the possibility that p73 may be a second-order clock-
controlled gene. The transcriptional regulation of p73 has been
investigated in some detail. The gene is negatively controlled by
C-EBPα and is activated by Early growth response 1 (Egr1) (18,
19). Treatment of cells with DNA-damaging agents leads to re-
lease of the repressive C-EBPα from the promoter and tran-
scriptional up-regulation of p73 in an Egr1-dependent manner.
Of particular interest, it was recently reported that Egr1 might be
a clock-controlled gene (20, 21). These facts, considered together,
lead to certain predictions: First, Egr1 must be up-regulated in
CryDKO cells, and this up-regulation must be reversed by down-
regulation of BMAL1. Second, it would be expected that BMAL1
will bind to theEgr1 promoter and, finally, both Egr1 and C-EBPα
are expected to bind to the p73 promoter where the binding of C-
EBPα but not of Egr1 must be affected by UV irradiation.
We tested these predictions in experiments summarized in Figs.
2 and 3. As would be predicted for a clock-controlled gene, the
level of Egr1 is elevated both in CryDKO and p53KOCryDKO cells
(Fig. 2A). Moreover, in accordance with the prediction, the ele-
vation of Egr1 as a consequence of Cry down-regulation can be
reversed by BMAL1 knockdown (Fig. 2B), consistent with regu-
lation of Egr1 by the primary circadian feedback loop. In support
of the model for positive regulation by BMAL1 and negative
regulation by Cry, chromatin immunoprecipitation (ChIP) anal-
ysis revealed occupancy of the Egr1 E-box sequence element by
BMAL1, which is enhanced in the absence of Cry1/2 and abol-
ished by down-regulation with BMAL1 (Fig. 2C). Finally, when
the occupancy of the p73 promoter was analyzed by ChIP, we
found greatly enhanced occupancy by Egr1 in p53KOCryDKO cells,
which was not affected by UV irradiation (Fig. 3A). In contrast,
Cry mutation had no effect on binding of C-EBPα to the p73
promoter, but the occupancy of the promoter by C-EBPα was
drastically reduced after UV irradiation (Fig. 3A). Taken to-
gether, these data support the model that p73 expression is reg-
ulated by the clock-controlled Egr1 and by the DNA damage-
Fig. 1. Regulation of p73-mediated apoptosis by the circadian clock. (A) Time course of p73 induction in p53KO and p53KOCryDKO cells analyzed by immu-
noblotting and RT-PCR. The quantitative results of the levels of p73 protein and mRNA (Bottom) are means ± SD (n = 3). The UV dose was 10 Jm−2. (B)
Immunoblots showing the role of p73 in UV-induced apoptosis in p53KOCryDKO cells. Cells were transfected with the indicated siRNAs, irradiated with 10 Jm−2,
and then analyzed for apoptosis by probing for cleaved PARP (c-PARP) and cleaved caspase 3 (c-Casp3). (C) Enhanced apoptosis observed in cryptochrome-
deficient cells is reversed by down-regulation of BMAL1. p53KO mouse embryonic fibroblasts were transfected with the indicated siRNAs and UV-irradiated
where indicated with 10 Jm−2, and apoptosis was probed by immunoblotting for cleaved PARP and cleaved caspase 3.
Fig. 2. Egr1 is a clock-controlled gene. (A) Overexpression of Egr1 in cryp-
tochrome-deficient cells. Mouse fibroblasts of the indicated genotypes were
analyzed for expression of Egr1 and C-EBPα, the two main regulators of p73.
Actin was used as a loading control. (B) Egr1 expression is regulated by the
circadian clock. p53KO fibroblasts were transfected with the indicated siRNAs
and the levels of Egr1 and C-EBPα were probed by immunoblotting. (C)
Binding of BMAL1 (positive arm of the core circadian clock) to the Egr1
promoter. Fibroblasts of the indicated genotypes were transfected with
control (Ctrl) or BMAL1 siRNA and then the occupancy of the Egr1 promoter
by BMAL1 was analyzed by ChIP. Note the elevated ChIP values in p53KOC-
ryDKO cells relative to p53KO cells, indicating that Cry reduces the occupancy
of target promoters by BMAL1 (P < 0.05, n = 3).



















controlled C-EBPα, and hence, in Cry-null mutants, increased
expression of Egr1 combined with UV damage-induced dissoci-
ation of C-EBPα from the p73 promoter leads to a high level of
p73 production and the consequent apoptosis. In further support
of this model, we find that both in p53KO and in p53KOCryDKO cells,
down-regulation of Egr1 by siRNA significantly reduces UV in-
duction of p73 and abolishes apoptosis (Fig. 3B).
Regulation of p73 by the Circadian Clock in Human Cancer Cell Lines.
The apoptosis-enhancing effect of Cry mutation seems to be
unique to both mouse and human p53 mutant cells, because in
cells with wild-type p53 the p53-driven apoptosis is expected to be
dominant and thus obscure any contribution of the p73 pathway
(22). This prediction was tested by analyzing apoptosis in two p53
mutant and one p53 wild-type human cancer cell lines. As seen in
Fig. 3C in the Caco-2 and H1299 cell lines in which p53 is not
functional, down-regulation of Cry enhances p73 expression and
increases apoptosis after UV irradiation. In contrast, in the A549
cell line with a functional p53, even though down-regulation of
Cry leads to enhanced levels of p73 after UV, this up-regulation
of p73 is not accompanied by enhanced apoptosis (Fig. 3D) be-
cause apparently the UV-induced p53 is sufficient to cause
maximal level of apoptosis, which cannot be further enhanced by
increased p73. Taken together, the data in Figs. 2 and 3 show that
Egr1 is a clock-controlled gene and that p73 is a second-order
clock-controlled gene that plays a prominent role in promoting
apoptosis and clonogenic death (Figs. S6 and S8) in p53-null cells
lacking cryptochrome.
Enhancement of the Efficacy of Oxaliplatin by Cryptochrome
Disruption. Next, we wished to determine whether the enhance-
ment of apoptosis induced by genotoxic agents (intrinsic apo-
ptosis) (23, 24) by Cry mutation in p53 mutant cells can be used
for therapeutic purposes. Cisplatin and its second- and third-
generation derivatives are UV-mimetic agents that kill cells
mainly by producing intrastrand diadducts in DNA (25, 26).
Hence, we reasoned that cryptochrome disruption might enhance
the sensitivity of p53-null cells and tumors to killing by platinum
derivatives. We performed our chemotherapy experiments with
oxaliplatin, which is the drug of choice for treating colorectal
cancers, among others (26). First, we established that Cry muta-
tion sensitizes transformed p53-null cells to oxaliplatin-induced
p73 up-regulation and to killing by apoptosis (Fig. S9). This was to
be expected, because the major DNA lesions induced by this drug,
the GG, AG, and GXG diadducts, can only be repaired by nu-
cleotide excision repair, as are the cyclobutane pyrimidine dimer
and the (6-4) photoproduct (27). Then, we used a mouse tumor
model to test the efficacy of oxaliplatin in treating clock-normal
and clock-disrupted cancers by oxaliplatin.
Tumor xenografts were established in 6-wk-old female immu-
nodeficient mice by injection of oncogenically transformed p53KO
and p53KOCryDKO cells (7). Each animal received, by sub-
cutaneous injection, p53KO cells in one flank and p53KOCryDKO
cells in the other. The tumors of both genotypes grew at the same
rate (Fig. S10), and when the tumor volumes reached 0.1 cm3,
oxaliplatin treatment was initiated. The mice received 10 mg/kg
oxaliplatin once a week for 3 wk. Fig. 4A shows that administra-
tion of oxaliplatin drastically inhibits 2-[18F]deoxyglucose ([18F]
FDG) uptake in the p53KOCryDKO tumor compared with the
p53KO tumor. In parallel with this effect on metabolism, oxali-
platin suppressed tumor growth in p53KOCryDKO but had no
measurable effect on the growth rate of the p53KO tumor (Fig.
4B). In vivo measurements of caspase-3 activity of the two groups
of tumors after the drug treatment revealed that there was mas-
sive apoptosis in the tumor with the p53KOCryDKO genotype (Fig.
4C), which provides a mechanistic explanation of the favorable
response to oxaliplatin of tumors of this genotype. Thus, the tu-
mor xenograft study supports the prediction based on apoptosis
and toxicity experiments with cultured cells that cryptochrome
disruption in p53-null cells makes them more sensitive to che-
motherapy by oxaliplatin.
Conclusion
In Fig. 5, we summarize the findings of this study: Egr1 is a clock-
controlled gene and p73 is a second-order clock-controlled gene
that is regulated through Egr1 by the clock and through C-EBPα
by the DNA damage response reaction. In the absence of Cry,
Egr1 is elevated, and upon DNA damage the release of C-EBPα
from the p73 promoter leads to Egr1-activated up-regulation of
p73 and thus p53-independent apoptosis. These findings suggest
that in p53 mutant tumors, which constitute about 50% of all
human tumors, targeted inhibition of Cry may improve the ef-
ficacy of platinum-based chemotherapy or of combination che-
motherapy that includes cis-platinum drugs.
Materials and Methods
Establishment of p53−/− and p53−/−Cry1−/−Cry2−/− Tumor Cell Lines. Cell lines
were generated from the p53−/− and p53−/−Cry1−/−Cry2−/− mouse strains as
described previously (7, 27). To obtain cell lines, skin patches from the backs
of mice at the age of 3 mo were taken under sterile conditions, cut into small
pieces, placed in four- or six-well plates, and incubated for 1 wk to let the
fibroblasts migrate into the wells. The fibroblasts were passaged at least
three times before using them in any experiments. Primary wild-type skin
Fig. 3. Requirement for Egr1 in clock-mediated p73-dependent apoptosis.
(A) Effect of UV on occupancy of the p73 promoter by Egr1 and C-EBPα in the
absence and presence of cryptochrome. Mouse fibroblasts of the indicated
genotypes were irradiated with 10 Jm−2 where indicated and the promoter
binding of Egr1 and C-EBPα was determined by ChIP. Note that Cry mutation
enhances Egr1 binding (P < 0.05, n = 3), which is not affected by UV. In
contrast, Cry mutation has no effect on C-EBPα binding, which is significantly
reduced by UV irradiation. (B) Elevated Egr1 in Cry mutant cells is responsible
for enhanced UV-induced apoptosis. Mouse fibroblasts of the indicated
genotypes were transfected with the indicated siRNAs, irradiated with UV,
and then analyzed for C-EBPα and p73 expression directly by immunoblot-
ting and for apoptosis by immunoblotting for cleaved PARP and caspase 3.
(C) Effect of cryptochrome down-regulation in p53-null human cell lines on
Egr1 and p73 expression and UV-induced apoptosis. The cell lines were
transfected with the indicated siRNAs, irradiated with 10 Jm−2 of UV where
indicated, and probed for apoptosis by immunoblotting. (D) Effect of cryp-
tochrome down-regulation on Egr1 and p73 expression and UV-induced
apoptosis in a human tumor cell line with wild-type p53. Whole-cell lysates
were analyzed by immunoblotting.
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fibroblasts were isolated in the same manner, and passaged eight times
without the appearance of spontaneously immortalized clones. Wild-type
mouse embryonic fibroblasts were kindly provided by Norman Sharpless
(University of North Carolina, Chapel Hill, NC). For Ras-induced oncogenic
transformation, cells were seeded into 10-cm plates and transfected with
250 ng of pEGFP-N1 (Clontech) and/or 5 μg of Ras pT24 vector (7) using
FuGENE 6 reagent (Roche). The next day, cells were divided into three plates
and incubated for 18 d. The plates were stained with Giemsa and colonies of
oncogenically transformed cells were counted visually, and the fraction of
transformed cells was normalized for transfection efficiencies calculated by
countingGFP-positive cells in each plate. These cellsweremaintained inDMEM
(Life Technologies) supplemented with 10% FBS (Gemini Bio Product), 100
units/mL penicillin, and 100 μg/mL streptomycin (Life Technologies). The cells
weremaintained in an incubator at 37 °C under 5%CO2. TheCry1
−/−Cry2−/− cell
line has been described (27).
Human Cell Lines. H1299 cells were kindly provided by Shlomo Melmed
(Cedars-Sinai Medical Center, Los Angeles, CA). Caco-2 and A549 cells were
obtained from the American Type Culture Collection. These cells were grown
in DMEM with 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin
at 37 °C under 5% CO2.
Clonogenic Survival Assay. UV survival assays were performed as described
previously (27) using a fluence in the range of 0–10 Jm−2. For oxaliplatin
survival assays, cells were seeded into six-well plates at 105, 5 × 104, and 2 ×
104 cells per well in duplicate and incubated in growth medium for 10–14 h.
The cells were washed and incubated with 0–20 μM oxaliplatin for 2 h. Then,
the cells were washed with PBS twice, growth medium was added, and cells
were incubated for 10–14 d. Cells were then fixed for 20 min in 3:1 meth-
anol:acetic acid, rinsed with water, stained with 5% methylene blue, and
counted. Colonies containing >50 cells were scored, and survival was calcu-
lated from the ratio of the number of colonies in the treated samples to
those in the control plates.
Immunoblot Analysis. Antibodies were from the following sources: Egr1,
PARP, cleaved caspase 3, and p53 (Cell Signaling Technology), p63 (Novus
Biologicals), p73 (Upstate Biotechnology), C-EBPα (Thermo Scientific), and
actin and cyclophilin B (Santa Cruz Biotechnology). Mouse Cry1 (monoclonal)
and Cry2 (polyclonal) antibodies were prepared in our laboratory (27).
Conventional immunoblotting procedures were used to detect the target
proteins: Cells were collected, washed once in cold PBS, and then scraped in
TEGN buffer (10 mM Tris, pH 8, 1 mM EDTA, 10% glycerol, 0.5% Nonidet
P-40, 400 mM NaCl, 1 mM DTT, 0.5 mM phenylmethylsulfonylfluoride, and
protease inhibitor mixture containing 1 M benzamidine, 3 mg/mL leupeptin,
100 mg/mL bacitracin, and 1 mg/mL α2 macroglobulin) and incubated on ice
for 15 min. Lysates were then cleared by centrifugation at 20,000 × g for 10
min. Total protein concentration was determined via the Bio-Rad protein
assay. Equal amounts of protein were separated on 10% SDS/PAGE and the
proteins were transferred to nitrocellulose membranes (Schleicher and
Schuell). The membranes were then blocked for 1 h in a PBS solution con-
taining 5% nonfat milk powder and 0.1% Tween-20 and then probed with
primary antibody overnight in 1% milk, 0.1% Tween-20 in PBS. After wash-
ing, membranes were incubated for 1 h with horseradish peroxidase-linked
secondary antibody (Sigma) in 1% milk, 0.1% Tween-20 in PBS. Finally, after
three 5-min washes in 0.1% PBS/Tween-20, proteins were visualized by en-
hanced chemiluminescence (Amersham Biosciences). Band intensities were
quantified with ImageQuant 5.2 software (Molecular Dynamics).
Chromatin Immunoprecipitation. ChIP was performed according to manu-
facturer’s instructions (Sigma) with some exceptions. Protein–DNA com-
plexes incubated with rabbit polyclonal antibodies against BMAL1 (Bethyl
Laboratories), rabbit monoclonal antibody directed against Egr1 (44D5; Cell
Signaling Technology), rabbit polyclonal antibody against C-EBPα (PA1-825;
Thermo Scientific), or equivalent IgG control (Cell Signaling Technology)
were precipitated using protein A/G-conjugated agarose beads (Calbio-
chem). Protein–DNA crosslink was resolved and followed by quantitative
real-time PCR using SYBR green master mix (Applied Biosystems) with the
primers listed in Table S1.
Chemicals and Treatment. Cells were treated with 20 μg/mL cycloheximide
(Sigma) or 5 μg/mL actinomycin D in DMEM as indicated and then protein
stability was assayed by conventional immunoblotting. The caspase-3 inhibitor
Fig. 4. Effect of cryptochrome mutation on treating cancer with p53-null mutation. NOD/SCID mice bearing a p53KO tumor xenograft on the left flank (*)
and a p53KOCryDKO tumor xenograft on the right flank (**) received oxaliplatin intraperitoneally at 10 mg/kg once a week for 21 d and various tumor-related
metrics were recorded. (A) Tumor metabolism. MicroPET scan recorded 1 h after [18F]FDG injection on day 38 after xenograft injection. (Right) The quan-
tification of [18F]FDG signal calculated as the ratio of % injected dose (ID) at the ROI (circle) to the % ID at a background region. Error bars represent means ±
SD (n = 4). The dorsal aspect is shown. (B) Tumor growth. Arrows indicate days of oxaliplatin injection following the xenograft injection on day 0. The
oxaliplatin treatment was initiated after tumor size had reached 0.1 cm3. Error bars represent means ± SD (n = 10). (C) Oxaliplatin-induced apoptosis in
xenografts. NOD/SCID mice were injected with p53KO-Luc cells in the left flank (*) and p53KOCryDKO-Luc cells in the right flank (**). One week later, weekly
injections with oxaliplatin were initiated. After the third round of oxaliplatin injection, Z-DEVD-aminoluciferin prosubstrate for caspase 3 was administered
intraperitoneally and 10 min later, bioluminescence was measured in the ROI (circle) drawn over the tumor. Quantitative analysis (Right). Error bars represent
means ± SD (n = 4).
Fig. 5. Model for targeting the clock to improve the efficacy of oxaliplatin
treatment of p53-null tumors. Cry regulates Egr1, which transactivates p73.
With Cry inactive, Egr1 is up-regulated. Following oxaliplatin-induced re-
moval of C-EBPα from the p73 promoter, Egr1 causes massive production of
p73 and enhanced apoptosis.



















Z-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-CH2F (Z-DEVD-FMK) (R&D Systems) was
used at a final concentration of 25 μM.
RNA Interference and Transfection. For RNAi experiments, cells at 70% con-
fluency were transfected using DharmaFECT (Dharmacon Research) accord-
ing to the manufacturer’s directions for transfection of ON-TARGET plus
SMARTpool siRNA duplexes specific for each target purchased from Dhar-
macon Research: mouse Cry1 (L-040485-01-0005), mouse Cry2 (L-040486-00-
0005), mouse Per1 (L-040487-00-0005), mouse Per2 (L-040489-01-0005),
mouse BMAL1 (L-040483-01-0005), mouse Egr1 (L-040286-00-0005), mouse C-
EBPα (L-040561-00-0005), mouse p73 (L-043871-00-0005), mouse cyclophilin
B (D-001820-20-05) as a control, human Cry1 (L-015421-00-0005), human
Cry2 (L-014151-01-0005), human cyclophilin B (D-001820-10-05) as a control,
or nontargeting siRNA (D-001810-10-05) as a control. The siRNA experiment
was carried out for 48 h, at which time cells were harvested and the extent
of knockdown of the target genes was assessed by immunoblotting or RT-
PCR. For the determination of the effect of gene knockdown on clonogenic
survival, after treating the cells with siRNA for 24 h, the cells were plated at
low density to ensure the formation of 400 colonies per six-well plate in the
absence of UV irradiation. Following plating, cells were incubated in growth
medium for 10–14 h and treated with UV at a fluence rate of 0.5 Jm−2·s−1
from a germicidal lamp for the appropriate doses. The cells were then in-
cubated for 9–10 d until colonies were readily visible. The specificity of the
antibodies and siRNAs used are shown in Fig. S11.
RT-PCR. RNAwas extracted from cell pellets using an RNeasyMini Kit (Qiagen)
and quantified by UV-vis spectrophotometry. The cDNAs were generated by
reverse transcription with random hexamers using the ImProm-II Reverse
Transcription System (Promega). Then RT-PCRwas performedwith the primers
listed in Table S2. Quantitative real-time PCR was then performed using the
Expand High Fidelity PCR System (Roche). Conditions for linear amplification
were established through template and cycle curves. PCR products (40% of
reaction mixture) were then separated on 2% agarose gels and bands were
visualized with ethidium bromide staining. Quantification of p73 induction
was performed with ImageQuant 5.2 software (Molecular Dynamics).
Tumor Xenograft Model. Animal studies were conducted in accordance with
the regulations of the National Institutes of Health and the Institutional
Animal Care and Use Committee of the University of North Carolina School of
Medicine. Tumor xenografts were established in 6-wk-old female immuno-
deficient NOD/SCID mice by subcutaneous inoculation of 2 × 106 cells mixed
with an equal volume of Matrigel (BD Biosciences) into both flanks. The
NOD/SCID mice were bred and kept under defined-flora pathogen-free
conditions at the AAALAC-approved Animal Facility of the Division of Ex-
perimental Radiation Oncology, University of North Carolina. Oxaliplatin at
10 mg/kg was administered intraperitoneally once a week for 21 d. Tumor
volume and body weight were recorded every 3 d. Tumor size was measured
with a caliper in three mutually perpendicular diameters (a, b, and c) and the
volume was calculated as V = (π/6) × a × b × c.
Micro Positron Emission Tomography Imaging. Whole-body images of the
biodistribution of [18F]FDG tracers in mice were obtained by micro positron
emission tomography (microPET) scans. Mice were kept warm under gas an-
esthesia (2% isoflurane) and injected with [18F]FDG intraperitoneally. A 1-h
interval for uptake was allowed between probe administration and microPET
scanning. Data were acquired using a Siemens Preclinical Solutions MicroPET
Focus 220 instrument. MicroPET data were acquired for 10 min and were
reconstructed using statistical maximum a posteriori probability algorithms
into multiple frames. The spatial resolution of microPET is ∼1.5-mm, 0.4-mm
voxel size. Three-dimensional regions of interest (ROI) were drawn using
AMIDE software (Andreas Loening, Stanford University, Palo Alto, CA). Color
scale is proportional to tissue concentration, with red being the highest and
lower values in yellow, green, and blue.
InVivo ImagingofCaspase-3Activity.For preparation of Z-DEVD-aminoluciferin,
10 mg of VivoGlo Caspase-3/7 substrate (Promega) was dissolved in 67 μL of
surfactant mix (70 μL Tween-80, 640 μL PEG 400, and 290 μL N,N-dimethyla-
cetamide) and then added to 100 μL of 5% glucose in water. The mixture was
vortexed to make a homogeneous suspension and injected intraperitoneally
into tumor-bearing mice (100 μL per mouse). Ten minutes after Z-DEVD-
aminoluciferin injection, the mice were imaged with IVIS-200 (Xenogen) for in
vivo photon counting of bioluminescence. The photon emission intensity
(photons/s) of each mouse is indicated in a rainbow bar scale.
Statistical Analysis. Results are shown as means ± SD, which were performed
using a two-tailed t test.
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